DCPH - Deciphera initiated at buy at Cowen on Qinlock growth pipeline; sees 68% upside

• Deciphera Pharmaceuticals ( NASDAQ: DCPH ) has been initiated as a buy at Cowen based on growth in sales of its advanced gastrointestinal stromal tumor treatment Qinlock (ripretinib) and its pipeline.
• The firm has a $25 price target (~68% upside based on Friday's close).
• Analyst Tyler Van Buren said that Decipera ( DCPH ) pipeline is "poised to break out" and a significant catalyst could come next month at the European Society for Medical Oncology (ESMO) annual meeting with data on vimseltinib and DCC-3116.
• Vimseltinib is in phase 1/2 for tenosynovial giant cell tumor, while DCC-3116 is in phase 1 for RAS/RAF mutant cancers in combination with Mekinist (trametinib).
• He added he sees peak sales of both candidates at a combined ~$1.3B.
• Seeking Alpha's Quant Rating view Deciphera as a buy with high marks for momentum, growth, and revisions .

For further details see: